News
  Date Title View
Jul 6, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of th...
Jun 16, 2016
- Trial On Track for Topline 90-day Interim Efficacy Readout in Q4 2016 - -Rocket 4 Designed for EU Filing; Not Required for US NDA Filing- IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on...
Jun 2, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that comp...
May 5, 2016
Trial On Track for Topline 90-day Efficacy Readout in Q3 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced...
May 4, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vic...
May 2, 2016
Company on Track to File NDA in 3Q 2016 for Rhopressa™ (netarsudil ophthalmic solution) 0.02% Mercury 1 Phase 3 Topline Readout for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Also Expected in 3Q 2016 Conference Call and Webcast Today, May 2, at ...
Page: FirstPrevious
4
= add release to Briefcase